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Abstract 
 
Background: The Valencian Autonomous Community (Spain) has implemented a scheme of purchasing 
services with the participation of public and private providers. Five districts are managed using Public-
Private Partnership. The financing model is capitation and inter-centre invoice. The pharmaceutical 
benefits are not included in the per capita assignment. 
 
Objectives: Modeling and explaining pharmacy expenditure using electronic prescriptions drug data. 
 
Methods: A database of electronic prescription corresponding to 625,246 patients between Nov 2008 
and Oct 2009 was used to run four linear models that explain the pharmaceutical expenditures. We take 
as dependent variable the neperian log of total pharmacy annual cost per patient in the primary health 
setting. The independent variables used combine demographics with revised classification in 18 chronic 
conditions obtained from the anatomical therapeutic chemical classification index (ATC).  
 
Results: The retrospective model selected included: gender, pharmaceutical co-payment status and 8 
dummy variables for the number of chronic conditions of each patient from 1 to 8 or more. The 
goodness-of-fit achieved is measured in R2 of 57%.  
 
Conclusions: These models must be considered in the current capitation system for pharmaceutical 
budgeting in a primary care setting established at regional level, as is the case in the Valencian 
Autonomous Community. The use of diagnostics and information regarding hospital encounters appears 
to be a complementary option for refining models of capitation of pharmaceutical and total health 
expenditure. 
 
 
 
Author Keywords: Prescribed drugs, pharmaceutical expenditure, chronic condition, risk adjustment; 
capitation payments.  
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1. Introduction 
The National Health Systems which have introduced an internal market [1] to make resource allocation 
in health care more efficient [2] need risk adjustment models to achieve success. This is the case with 
the Spanish National Health System, which is completely decentralised to Autonomous Regions 
(Comunidades Autónomas). 
The Valencian Regional Government, covering an area with a population of about 5,000,000, organizes 
health services through its Regional Health Authority (Conselleria de Sanidad), with a health care budget 
that is more than 40% of the total regional government’s annual expenditure. 
Since 2000 the Valencian Regional Health system has been involved in a process of creating an internal 
market between health districts to stimulate efficiency. 
The Health System’s functions of financing, purchasing and provision of services are separated from 
each other. The Regional Health Authority has the functions of stewardship [3], the Valencian Health 
Agency (Agencia Valenciana de Salud) is the purchaser and the 24 Health Districts (Departamentos de 
Salud) are the provider of services. Five of these districts are privately managed, using a formula of 
public-private partnership, denominated administrative concession. This model consists of an 
agreement between the public purchaser and a private company to construct a hospital and manage the 
health district for at least 10 years. After this period the hospital reverts to public ownership. 
The financing model selected was capitation and inter-center invoicing - money following patient [4]. 
The health district receives an annual per capita quantity to attend to its assigned population: the flow 
of outgoing and incoming patients from other health districts generates an inter-center turnover to 
establish the corresponding balance1.  
The pharmacy budget in primary health care is currently independent of this per capita assignment. The 
Valencian Health Agency is interested in a model of a risk adjustment system to control pharmacy 
spending. 
At the same time, pharmaceutical spending is undergoing a very high growth, approximately 30% of 
overall health expenditure [5]. The Regional Health Authority has been studying a model of adjusting 
pharmaceutical expenditure based on chronic conditions and using electronic prescriptions drug data. 
 
 
Adjusting pharmaceutical expenditure background 
 
The starting point for our research is the Von Korff [6] approach. This group develops the Chronic 
Disease Score (CDS). They used population based automated outpatient pharmacy data in the United 
States (US) to construct a measurement of chronic disease status. The variables used were age, gender 
and health care visits. A replication of this study showed the validity of the model [7]. A refined CDS was 
developed including 28 conditions, age and sex, explaining 10% of the variation in total medical 
expenditure [8].  
 
                                                            
1 In a Public-Private Partnership (PPP) health system, if a patient is treated anywhere other than his corresponding 
health district, the PPP health district has to pay the full Diagnosis-Related Group (DRG) cost. If patients from other 
health districts are treated in a hospital of a PPP health district, this pays 80% of the DRG cost. For others services 
not included in DRGs there are tariffs with the same criteria. 
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Later, Malone [9] developed a chronic disease index using a medication database to approximate the 
number of chronic diseases a patient has. The index predicted the presence of three common diseases 
with a sensitivity of ≥ 75%, and of six common diseases with a specificity of ≥ 75%.  
 
Lamers [10] replicated and extended the study on the revised CDS using automated outpatient 
pharmacy data from one Dutch sickness fund. They clustered 28 chronic conditions into seven Pharmacy 
Cost Groups (PCGs) in function of similarities in future costs, explaining 10% of differences in the 
following year’s expenditures between patients. This gave an improvement of nearly twice the R2 of a 
model containing only demographic variables. 
 
Other studies showed the predictive accuracy and validity of PCG for the Dutch health system [11], [12]. 
The correlation between medication and 28 chronic conditions was studied. This study showed that for 
22 chronic conditions a majority of the prescriptions were for relevant diagnoses and therefore were 
considered indicative for specific chronic conditions [13]. 
 
Some models combining medicine code and diagnoses, Diagnostic Cost Groups, DCG/Rx [14] and 
Adjusted Clinical Groups ACG/Rx [15, 16], have proven their efficacy, but need diagnoses accuracy 
information that is not always available.  
 
In Spain, a recent study shows that the adjusted capitation models based on pharmaceutical 
consumption are more explicative than those based only on diagnostics and are of a similar capacity to 
those combining both [17]. 
 
The objective of this paper is to analyze the influence of classification of medications for chronic 
conditions on the pharmaceutical expenditure in a primary health care setting, in order to develop a 
capitation adjusted model.  
 
2. Methods 
 
Data 
 
A database of 12,893,852 electronic prescriptions from health centres of Valencia Health Agency 
between Nov 2008 and Oct 2009 corresponding to a population of 625,246 was used, where 417,986 
patients take some medicine. Each prescription contained patient identification, a code from the 
anatomical therapeutic chemical classification index (ATC-code) [18], cost and Defined Daily Doses 
(DDD) [19] and date. This information was linked with another database from the Population 
Information System with the following information for each person: age, gender, health district, health 
center and co-payment status. In Spain there is only co-payment for medicines. There are two 
categories of co-payment, co-payment level of 0% for pensioners and population without resources, and 
co-payment of 40% of price for the remaining. 
 
To avoid including incidental users of medications under chronic conditions, persons were classified as 
chronic condition based on at least four prescriptions for the particular condition in the period of time 
studied. 
 
The relation between medication and chronic conditions was studied using the revised CDS. This 
classification gives the ATC-code related with 25 chronic conditions. Table 1 shows information related 
to the 24 chronic conditions in primary care excluding HIV/AIDS. However, in this research only 18 
diseases were included. Following Lamers [13], anxiety and tension, pain, and pain and inflammation 
were also excluded as the diagnoses on the prescriptions were not relevant for these conditions. 
Furthermore, a group of experts (physicians and pharmacists) from the Regional Health Authority 
assessed the relation between drugs and diagnoses and eliminated malignancies, HIV/AIDS, renal 
disease and transplantation from the study. These diseases were excluded due to the drugs used by 
these patients being dispensed in hospitals. 
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Therefore a matrix was defined where the rows are the persons and the columns 18 chronic conditions, 
gender, age and co-payment status and pharmaceutical expenditure. 
 
 
Models 
 
To explore the association between annual costs per patient for each of the 18 chronic conditions, a 
factorial analysis was performed. 
 
Later, we developed four models where the dependent variable was always total pharmacy cost per 
person and year in a primary care setting. 
 
The models were estimated by means of ordinary least squares (OLS). Predictive performance of the 
model was evaluated by means of R2-value, the F Snedecor and T Student. The assumptions of 
normality, homoscedasticity and linearity were considered, and the logarithmic transformation was 
applied for the dependent variable2. Age was excluded due to the high correlation with the co-payment 
status (0.67). Once the models were obtained, the fulfillment of the three assumptions was proved 
through the analysis of the residuals.  
 
The first model independent variables are: gender (dummy variable 0 female -1 male), co-payment 
status (dummy variable 1 without and 0- 40% co-payment). These variables were also included in all 
models with the exception of co-payment, which was excluded in the fourth model. In the second model 
three factors out of five were included and (OLS) regression analysis of factor was estimated.  
 
The third model takes as independent variables one representative variable of each factor, selected by 
statistical and clinical criteria: hyperlipidemia (the highest correlated), depression (high correlated and 
high number of patients) and respiratory illness (high correlated and high number of patients) - all also 
as dummy variables. 
 
Finally, we explored the relation between the dependent variable and the number of chronic diseases. 
Thus, we take in this case as independent variables: gender and 8 dummy variables for groups from only 
1 chronic condition to 8 or more. The reason for which we have excluded the co-payment status from 
the model is because of its correlation with the number of chronic conditions. 
 
3. Results 
 
Pharmaceutical expenditure corresponding to chronic conditions amounts to 108,528,233 Euros 
addressed to a total of 173,991 patients, which means that 27.82% of the population have some chronic 
condition, and supposes 58.2% of the total pharmaceutical expenditure. Table 1 shows the cost and 
number of patients for each disease. 
 
The greatest cost is in drugs used to treat hyperlipidemia, at 17,075,134 €, followed by respiratory 
illnesses, at 12,392,042 € and diabetes, at 10,381,386 €.  These three pharmaceutical groups represent 
an expense of more than 36.7% of the total of drugs used for chronic conditions. The number of 
different chronic conditions suffered by each individual is determined by the number of different ATC 
groups. Figure 1 shows the number of chronic conditions related to age. The number of chronic diseases 
increases significantly from 50 years old until 75.  
 
Five factors (Table 2) were obtained by factorial analysis. Factor one is the most relevant and represents 
the majority of cardiovascular diseases (coronary and peripheral vascular, cardiac disease) and their risk 
factors (hypertension, hyperlipidemia and diabetes), gout is associated with this factor, but with low 
coefficient and communality. The second factor included neuropsychiatric diseases (depression, epilepsy 
                                                            
2 The proposed models are based on the normality of the variables. The compliance of the model will depend on 
the level of normality of its variables. As a result, the logarithm of the pharmaceutical expenditure is estimated as a 
better approach to its normal distribution. 
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and psychotic illness). The third covers respiratory disease, rheumatism and peptic acid disease. 
Thyroids disease and tuberculosis are included in the fourth factor. TBC is negative correlated with this 
factor. The two variables composing this factor are inversely related. Parkinson’s disease and Cystic 
fibrosis are included in the fifth. The five together explain 36.23% of the variance and the first three 
factors a 25.05%. Two variables were not significant, glaucoma and Crohn’s and ulcerative colitis.  
 
Table 3 shows the results of the four models. Statistical significance checked by an F-test and T Student 
was over 99% for all of them. 
 
The first model, sex and co-payment status has an R2-value of 14.7%. However, the more explicative 
variable is co-payment status. Women use more medicines than men. 
 
The clinical and statistical explanation of the second model is weak. The first factor groups different 
chronic conditions with high prevalence - diabetes, hypertension and hyperlipidemia. To mix these 
diseases in a single factor is to limit the interpretation. 
 
The third model, using the substitute variable of three factors (hyperlipidemia, depression and 
respiratory illness), reaches a 35.4% prediction, better than using the factors (20.7%) (second model). If 
the 18 chronic conditions had been applied, model four, the goodness of fit would have reached 57.2%. 
 
Undoing the neperian logarithm transformation of expenditure, from the coefficients of the fourth 
model we can calculate the spending average for each group of patients. Thus, in Euros, a healthy 
woman without a chronic condition has an annual average spending on medicines of 8.01 (e2.081) Euros 
and a man 5.47 (e2.081-0.381) Euros. But in the case of patients with 8 or more chronic conditions the 
average expenditure was 3,763.11 (e2.081+6.152) Euros for women and 2,570.87 (e2.081-0.381+6.152) for men. 
The proportion increases when the number of chronic conditions of the patient increases. In last two 
columns of table 3 we give average amounts for each group in Euros. 
 
4. Discussion 
 
This contribution addresses the question of pharmaceutical cost containment and enhancing primary 
care. The models explaining the healthcare expenses based on demographic data have been improved 
by the introduction of chronic condition variables and diagnostics. Our research is focused only on 
primary heath drug expenditure and probably does not explain the total health cost in primary health 
care but resolves a problem of Health Authorities that need tools to manage and control the 
pharmaceutical spending. 
 
The model would be improved if the cost of medications dispensed in hospitals were included. In such a 
case, diseases such as cancer, HIV/AIDS, renal disease and transplantation could be introduced into the 
model. 
 
The fourth model seems the most convenient for Health Authorities to use in capitation allocation of 
budget to health districts and cost control, due to of its goodness of fit. 
 
Recently some studies are using new systems of adjusting risk to explain health expenditures. Four are 
systems of diagnostic based risk adjusting: Diagnostic cost groups DCGs [20] , RxRisk model [21], 
Adjusted Clinical Groups (ACG) [22] and Clinical Risk Groups (CRG) [23-25]. 
 
Prinsze and Van Vliet [26], established that the combination of PCGs [13] and DCGs used in the Dutch 
social health insurance sector was complementary in the explanation of the health expenditure. This 
model’s R2 reached 22.8% in 2004.  
 
Our model is retrospective, which is why it achieves a higher goodness-of-fit for explaining only 
pharmacy expenditure in primary health care with less number of variables, while other models explain 
the total health expenditure (primary health and hospital care) for a prospective application [27]. The 
results for total health spending must be considered in others studies. 
6 
 
 
The variability in pharmacy costs was explained by ACG in Spanish health centers using patient 
electronic records [28]. This model is based on primary health care patient diagnostic; the explanation 
level is inferior to that obtained by us.  
 
To examine how the model predicts prospective expenditure, further research is needed, using 
information from two consecutive years [15].  
 
5. Conclusions 
 
The models presented here improve the accuracy of risk-adjusted models for pharmaceutical 
expenditure in primary health care in National Health Systems such as the Spanish, where drug 
expenditure is the focus of discussion regarding efficiency, cost containment and system sustainability. 
 
However, our models have been obtained for a population with determined features, which should be 
considered in any application of them where these features may vary. 
 
The selected model is useful for adjusting the pharmaceutical spending in primary health care when 
there is no available information related to diagnosis, or such information is limited. Pharmaceutical 
information can, however, be obtained from the electronic prescribing system. 
 
The use of diagnostics and information regarding hospital encounters appears to be a complementary 
option for refining models of capitation of pharmaceutical and total health expenditure.  
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Table 1. Number of Patients, Prescriptions and Cost by Chronic Condition 
 Chronic conditions / ATC-code Number of Patients 
Number of 
Prescriptions Total cost (€) 
Average cost 
(€/patient) 
% of patients 
with chronic 
condition 
Anxiety and tension 
N05B 38,558 500,909 1,371,736            35.58    22.16% 
Cardiac disease / ASCVD/CHF) 
 C01, C03C, C03EB01 25,910 343,366 2,704,798          104.39    14.89% 
Crohn’s and ulcerative colitis 
A07EC, (excluding A07EC01) 
809 9,054 364,253          450.25    0.46% 
Coronary and peripheral vascular disease 
C04AD03, B01A 36,844 452,839 5,998,675          162.81    21.18% 
Cystic fibrosis 
A09AA02 50 479 17,766          355.31    0.03% 
Depression  
N06AA, N06AB, N06AE, N06AF, N06AG, 
N06AX 
29,937 339,120 8,410,054          280.93    17.21% 
Diabetes  
A10A, A10B 27,586 447,481 10,381,386          376.33    15.85% 
Epilepsy 
N03A, (excluding N03AE01) 10,313 119,088 5,119,687          496.43    5.93% 
Glaucoma  
S01E 12,853 201,165 3,170,014          246.64    7.39% 
Gout  
M04A 6,803 56,758 170,991            25.13    3.91% 
Hyperlipidemia 
C10A 57,789 675,907 17,075,134          295.47    33.21% 
Hypertension  
C02, C03A, C07, C08, C09A, C09B, C03EA01 58,091 788,670 8,412,175          144.81    33.39% 
Malignancies 
L01, (excluding L01BA01) , L03AA02, 
L03AA03, L03AA10, A04AA 
595 8,108 3,682,997      6,189.91    0.34% 
Pain 
N02A 10,356 179,358 3,445,931          332.75    5.95% 
Pain and inflammation 
M01A 45,202 446,745 5,066,451          112.08    25.98% 
Parkinson’s disease 
N04B 
1,808 27,797 1,695,455          937.75    1.04% 
Peptic acid disease 
A02A, A02B 63,640 731,357 7,877,462  123.78    36.58% 
Psychotic illness (including bipolar disorders) 
N05A 8,485 135,328 8,672,691      1,022.12    4.88% 
Renal disease (including ESRD) 
 B03XA01, V03AE01 128 957 30,511          238.37    0.07% 
Respiratory illness, asthma 
R03 18,913 312,239 12,392,042          655.21    10.87% 
Rheumatologic conditions 
H02, M01CB, M01CC01, P01BA02, L01BA01, 
A07EC01 
4,911 71,601 875,878          178.35    2.82% 
Thyroid disorders 
H03A, H03B 8,716 50,843 157,945            18.12    5.01% 
Transplantations 
L04AA01, L04AA05, L04AA06, L04AX01 828 18,724 1,415,102      1,709.06    0.48% 
Tuberculosis  
J04A 231 1,769 19,100            82.68    0.13% 
Total patients with chronic condition 173,991 5,919,662 108,528,233          623.76    27.82%  
Total population  625,246  186,552,001 298.37     
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Table 2.  Results of Factorial Analysis of Variables 
 
Rotation has converged in 6 interactions. Method: Principal component analysis. Analytic rotation in factor analysis: Varimax with 
Kaiser. In brackets after the conditions the correlation coefficient between its corresponding factor and this variable is shown. 
 
 
  
Components Variables (Chronic Conditions) 
Explained 
variance 
(%) 
1 
Hyperlipidemia 
(0.666) 
Hypertension 
(0.601) 
 
Cardiac 
Disease 
(0.544) 
Coronary and 
peripheral vascular 
disease (0.533) 
Diabetes 
(0.517) 
Gout 
(0.345) 12.295 
2 Epilepsy (0.671) 
Depression 
(0.632) Psychotic illness (0.611) 6.992 
3 
Rheumatologic 
(0.652) 
Respiratory 
illness, asthma 
(0.560) Peptic acid disease (0.388) 5.767 
4 Thyroid disorders (0.643) Tuberculosis (-0.544) 5.604 
5 Cystic fibrosis (0.789) Parkinson’s disease (0.556) 5.568 
Total variance (in %)  36.226 
   
Kayser- Meyer-Olkin index  0.755 
Bartlett’s test  
Chi-square approximation 401,309.44 
Gl 153 
Sig. 0.000 
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Table 3. Results of Models 
 
 Model 1 Model 2 Model 3 Model 4 
Cost by patient 
according to model 
4 (in Euros)* 
 Variables β β β β Women Men 
(Constant) 2.657 2.849 2.394 2.081   
Gender -0.489 -0.550 -0.412 -0.381   
Co-payment status 2.126 1.552 1.154    
Factor 1   0.689       
Factor 2   0.415       
Factor 3   0.267       
Hyperlipidemmia     3.069     
Depression     2.601     
Respiratory illness     2.953     
1 chronic condition       3.746 339.34 231.83 
2 chronic condition       4.480 706.98 482.99 
3 chronic condition       4.907 1,083.55 740.26 
4 chronic condition       5.213 1,471.44 1,005.26 
5 chronic condition       5.465 1,893.15 1,293.36 
6 chronic condition       5.697 2,387.50 1,631.08 
7 chronic condition       5.928 3,007.91 2,054.94 
8 o more       6.152 3,763.11 2,570.87 
N (625,246)           
Mean squared error 5.863 5.450 4.436 2.940   
R2 0.147 0.207 0.354 0.572   
F 53,680.449 32,573.217 68,608.995 92,878.019   
Dependent variable was the neperian logarithm of annual cost in Euros per patient. 
*The algorithm for women is e2.081-0.381+β, and men e2.081+β 
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Figure 1. Patient distribution by number of chronic diseases and age. 
 
 
 
 
